Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

8.7%

2 terminated/withdrawn out of 23 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

0 of 20 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

16(69.6%)

Phase 2

6(26.1%)

Phase 3

1(4.3%)

23Total

Phase 1(16)

Phase 2(6)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT00655395Phase 1Terminated

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Role: collaborator

NCT00354276Phase 2Unknown

VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia

Role: lead

NCT00282022Phase 2Completed

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

Role: lead

NCT00064064Phase 2Completed

3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer

Role: lead

NCT00054015Phase 2Completed

3-AP in Treating Patients With Advanced Prostate Cancer

Role: lead

NCT00112554Phase 3Completed

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

Role: lead

NCT00064051Phase 2Completed

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Role: lead

NCT00083187Phase 2Completed

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Role: lead

NCT00304005Phase 1Completed

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

Role: lead

NCT00004213Phase 1Completed

3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors

Role: lead

NCT00064090Phase 1Completed

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

Role: lead

NCT00049686Phase 1Completed

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

Role: lead

NCT00006218Phase 1Completed

3-AP in Treating Patients With Advanced Cancer

Role: lead

NCT00025129Phase 1Completed

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

Role: lead

NCT00098436Phase 1Completed

Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias

Role: lead

NCT00024323Phase 1Completed

Combination Chemotherapy in Treating Patients With Advanced Cancer

Role: lead

NCT00016874Phase 1Completed

3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer

Role: lead

NCT00004216Phase 1Completed

VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy

Role: lead

NCT00049699Phase 1Completed

VNP40101M in Treating Patients With Advanced or Metastatic Cancer

Role: lead

NCT00006254Phase 1Completed

VNP20009 in Treating Patients With Advanced Solid Tumors

Role: lead